Summary Safety Review - ULORIC (febuxostat) - Assessing a Possible Risk of Drug Reaction/Rash with Eosinophilia and Systemic Symptoms (DRESS)
Health Canada carried out a safety review after finding international cases of DRESS suspected of being linked with the use of Uloric (febuxostat). DRESS describes a group of rare, but serious and potentially life-threatening, side effects of a medication, with symptoms such as fever, severe skin rash with swollen face or peeling of the skin over large areas of the body, etc. These reactions usually happen two weeks to two months after starting a medication.
- Publisher
- Health Canada
- Resources
- 2
- Catalogue metadata updated
- 2024-05-10
Data overview
- Formats
- HTML
- File languages
- English, French
Official sources and licences
Resources
- Summary Safety Review - ULORIC (febuxostat) - Assessing a Possible Risk of Drug Reaction/Rash with Eosinophilia and Systemic Symptoms (DRESS) (French, HTML) HTML
- Summary Safety Review - ULORIC (febuxostat) - Assessing a Possible Risk of Drug Reaction/Rash with Eosinophilia and Systemic Symptoms (DRESS) (English, HTML) HTML